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Objectives The aim of this study was to investigate impact of metabolic syndrome (MS) on outcomes of catheter ablation in
patients with atrial fibrillation (AF) in terms of recurrence and quality of life (QoL).
Background MS, a proinflammatory state with hypertension, diabetes, dyslipidemia, and obesity, is presumed to be a close
associate of AF.
Methods In this prospective study, 1,496 consecutive patients with AF undergoing first ablation (29% with paroxysmal AF,
26% with persistent AF, and 45% with long-standing persistent AF) were classified into those with MS (group 1;
n  485) and those without MS (group 2; n  1,011). Patients were followed for recurrence and QoL. The Medi-
cal Outcomes Study SF-36 Health Survey was used to assess QoL at baseline and 12 month after ablation.
Results After 21  7 months of follow-up, 189 patients in group 1 (39%) and 319 in group 2 (32%) had arrhythmia recur-
rence (p  0.005). When stratified by AF type, patients with nonparoxysmal AF in group 1 failed more frequently
compared with those in group 2 (150 [46%] vs. 257 [35%], p  0.002); no difference existed in the subgroup with
paroxysmal AF (39 [25%] vs. 62 [22%], p  0.295). Group 1 patients had significantly lower baseline scores on all
SF-36 Health Survey subscales. At follow-up, both mental component summary (5.7  2.5, p  0.001) and physical
component summary (9.1  3.7, p  0.001) scores improved in group 1, whereas only mental component sum-
mary scores (4.6  2.8, p  0.036) were improved in group 2. In the subgroup with nonparoxysmal AF, MS, sex,
C-reactive protein 0.9 mg/dl, and white blood cell count were independent predictors of recurrence.
Conclusions Baseline inflammatory markers and the presence of MS predicted higher recurrence after single-catheter abla-
tion only in patients with nonparoxysmal AF. Additionally, significant improvements in QoL were observed in
the post-ablation MS population. (J Am Coll Cardiol 2012;59:1295–301) © 2012 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.051Metabolic syndrome (MS), a proinflammatory state, is a
cluster of cardiovascular risk factors including obesity, hy-
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2011, accepted November 22, 2011.pertension, diabetes, and dyslipidemia (1). As earlier studies
have implicated many components of MS, namely, hyper-
tension, diabetes, and obesity, to be prominent risk factors
for atrial fibrillation (AF), a strong association between MS
and AF is well evident (2). A fully efficient treatment
strategy for AF is yet to be established, because of limited
See page 1302
understanding of the complex pathophysiology of the
disease (3). The most commonly used therapeutic options
are antiarrhythmic drugs (AADs) and catheter ablation
using radiofrequency (RF) energy. Catheter ablation
provides an alternative therapy in patients with symp-
tomatic drug-refractory AF. However, the rate of success
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rhythm after ablation seems to
vary widely, ranging from 30%
to 85% (4,5). Both MS and AF,
as stand-alone conditions, trigger
physical, mental, and psychosocial
problems, which greatly impair
quality of life (QoL) (6). In this
prospective study, we aimed to
analyze the impact of coexistent
MS on long-term outcomes of cath-
eter ablation, such as recurrence-free
survival and QoL, in patients
with AF.
Inflammation is a common de-
nominator for both MS and AF. It
is known to play a significant role
in AF genesis and perpetuation.
Moreover, a proinflammatory state
evidenced by elevated levels of
C-reactive protein (CRP) is com-
monly observed in patients with
MS. Therefore, we additionally
sought to explore the role of in-
flammatory markers such as CRP
and total white blood cell (WBC)
ount at baseline in predicting AF recurrence after RF catheter
blation.
ethods
total of 1,496 consecutive patients with AF (439 [29%]
ith paroxysmal atrial fibrillation [PAF], 393 [26%] with
ersistent AF, and 664 [44%] with long-standing persistent
F) undergoing their first catheter ablations were enrolled
n this prospective study. Patients were classified into 2
roups: group 1, those with MS (n  485; mean age 64 
years; 77% men; mean left ventricular ejection fraction, 55
2%), and group 2, those without MS (n  1,011; mean age
2  11 years; 72% men; mean left ventricular ejection
fraction 57  9%). Baseline fasting blood samples were
obtained from all patients for the measurement of blood
glucose, lipid profile, CRP (Dimension RXL, Siemens
Healthcare, Erlangen, Germany), and total WBC count
(DXH 800, Beckman-Coulter, Brea, California). The CRP
cutoff value was set at 0.9 mg/dl, with values below and
above this cutoff considered normal and high, respectively.
Follow-up event recording and 7-day Holter monitoring
were performed at 3, 6, 9, and 12 months to check AF
recurrence.
The Medical Outcomes Study SF-36 Health Survey was
used to assess QoL at baseline and 12 months after ablation.
Self-administration mode was strictly followed for QoL
surveys; patients completed the survey in the privacy of their
homes, without any interference or help from the hospital
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
AFL  atrial flutter
AT  atrial tachycardia
BMI  body mass index
CI  confidence interval
CRP  C-reactive protein
HR  hazard ratio
MCS  mental component
summary
MS  metabolic syndrome
NPAF  nonparoxysmal
atrial fibrillation
PAF  paroxysmal atrial
fibrillation
PCS  physical component
summary
PV  pulmonary vein
QoL  quality of life
RF  radiofrequency
WBC  white blood cellstaff members or physicians.The SF-36 Health Survey assesses 8 different domains of
health status, namely physical functioning, role limitations due
to physical health, mental health, role limitations due to
emotional problem, social functioning, bodily pain, general
health, and vitality.
Two composite scores, physical component summary
(PCS) and mental component summary (MCS), were
computed from the SF-36 Health Survey subscales (PCS
included physical functioning, role limitations due to phys-
ical health, bodily pain, and general health, and MCS
included vitality, social functioning, role limitations due to
emotional problem, and mental health). All responses were
scored on a scale ranging from 0 to 100, with 100 repre-
senting the best possible functional status.
The following criteria were used to define different compo-
nents of MS (1,7): hypertension (blood pressure 130/85 mm
Hg or current antihypertensive medication use), diabetes (fast-
ing blood glucose  100 mg/dl or antidiabetic medication use),
yslipidemia (high-density lipoprotein 40 mg/dl in men and50
g/dl in women and serum triglycerides 150 mg/dl), and
besity (body mass index [BMI] 25 kg/m2 or abdominal
obesity, defined as waist circumference102 cm in men and88
m in women). According to the World Health Organization,
iabetes plus any 2 other risk factors is sufficient for the diagnosis
f MS (1).
AF type was categorized into 2 main groups for the study
urpose: PAF and nonparoxysmal atrial fibrillation
NPAF), which included persistent and long-standing per-
istent AF.
blation procedure. A standard catheter ablation protocol
as followed, as described in previous publications from our
roup (8,9). Periprocedural anticoagulation management
as done with continuous warfarin therapy before, during,
nd after the procedure, with the aim of maintaining the
nternational normalized ratio at 2 to 3.
AADs were discontinued 4 to 5 half-lives before ablation.
circular mapping catheter (Lasso, Biosense Webster,
iamond Bar, California) and a 3.5-mm open–irrigation tip
atheter (Thermocool, Biosense Webster) were used for ablation.
n patients with PAF, the pulmonary vein (PV) antrum, the
osterior wall between the PVs, and the area anterior to the
ight PVs along the left atrial septum were ablated using RF
nergy. The superior vena cava was also isolated if PV-like
otentials were recorded in that region. In patients with
PAF, the PV antrum, the posterior wall down to the
oronary sinus, and the left septal wall were isolated using
F energy. Additionally, the left atrium was mapped to
dentify complex fractionated atrial electrograms, which
ere ablated as well. Complex fractionated atrial electro-
rams were defined as electrograms composed of 2 or more
eflections and/or with continuous baseline activity or
lectrograms with cycle lengths 120 ms.
After ablation, in all patients, isoproterenol (up to 30
g/min) challenge was performed to locate any non-PV
triggers or to ensure electrical disconnection. All sites
showing firings were ablated.
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April 3, 2012:1295–301 MS and Ablation Outcome in AFNon-PV triggers were defined as any firing sites outside
the PV antrum.
End point. Improvement in QoL and long-term proce-
dural success were the 2 primary end points in this study.
Procedural success was defined as freedom from arrhythmia
(AF, atrial flutter [AFL], or atrial tachycardia [AT]) of30
s in duration without AADs at follow-up. Any episodes that
occurred during the first 12 weeks (the blanking period)
after the procedure were not considered recurrence (7,8).
Follow-up. Patients were discharged after overnight obser-
vation following ablation. They were discharged on their
previously ineffective AADs, which were continued during the
blanking period (12 weeks). After the blanking period, AADs
were discontinued. In case of recurrences after the blanking
period, patients were given previously ineffective AADs.
All patients were followed for 21  7 months after
blation. Follow-up was performed at 3, 6, 9, and 12
onths after the procedure, with a cardiologic evaluation,
2-lead electrocardiography, and 7-day Holter monitoring.
Patients were given event recorders for 5 months after
blation and were asked to transmit their rhythms every
ime they had symptoms compatible with arrhythmias and
t least twice a week even if asymptomatic. Any episode of
F or AT lasting 30 s was considered a recurrence.
QoL surveys were administered before ablation (baseline)
nd at 12-month follow-up.
tatistical analysis. Continuous data are described as mean 
D and categorical data as counts and percents. Student t
ests, chi-square tests, and Fisher exact tests were used to
ompare groups. Paired t tests were used to compare QoL
cores at baseline and 12-month follow-up. Pearson linear
orrelation coefficients (r values) and Spearman rank corre-
ation coefficients (rho values) were calculated to assess
orrelations between individual scales. Multivariate general
inear modeling was used to identify significant predictors of
oL improvement, and multivariate Cox models were used
o determine predictors of AF recurrence. All covariates
ere entered into the model on the basis of known or
xpected clinical relevance. Variables included in the model
ere age, sex, comorbidities, baseline ejection fraction, and
eft atrial diameter. The proportional hazards assumption
or the covariates was tested using Schoenfeld residual
nalysis. Tests were run to examine the presence of any
ignificant interactions and to identify possible multicol-
inearity of the covariates. The hazard ratio (HR) and 95%
onfidence interval (CI) of AF or AT recurrence were
omputed and are presented in the results. Time to event
as calculated from the procedure date and the date of
ecurrence. Recurrence-free survival over time was calcu-
ated using Kaplan-Meier analysis. The log-rank test was
sed to compare survival distributions across groups.
Further analyses were conducted to compare the magni-
ude of the association of MS, the composite predictor, with
utcome in contrast to its individual components. Separate
ultivariate Cox models were fitted with MS and theomponent predictors (keeping other baseline covariate wnchanged). The maximum likelihood estimates with asso-
iated p values from the models were used for the compar-
son. All tests were 2 sided, and p values 0.05 were
onsidered statistically significant. Analyses were performed
sing SAS (SAS Institute Inc., Cary, North Carolina).
esults
s expected, dyslipidemia, diabetes, hypertension, and
igher BMI were more frequently reported in group 1.
esides that, coronary artery disease, congestive heart fail-
re, and larger left atria were more prevalent in this group.
aseline CRP (median 5.18 mg/dl [interquartile range: 0.39
o 8.43 mg/dl] vs. 3.24 mg/dl [interquartile range: 0.31 to
.82 mg/dl], p  0.017] and total WBC (6,880  1,030 vs.
,572  1,007 per mm3, p  0.034) were significantly higher
n group 1. No difference in type of AF was noted. Clinical
haracteristics of the 2 groups are presented in Table 1.
During the procedure, non-PV triggers were more fre-
uently observed in the NPAF population of group 1
ompared with the NPAF patients in group 2 (270 [82%]
s. 379 [52%], p  0.001). At end of the procedure,
ersistence of arrhythmia was observed in 70 patients in
roup 1 (14.4%) and 122 in group 2 (12.1%) (p  0.201).
inus rhythm was achieved in these patients by cardiover-
ion. The mean fluoroscopic, RF, and procedural times were
ot different between the groups (Table 1). Compared to
atients with NPAF, those with PAF had significantly shorter
F times (60  30 min vs. 81  36 min, p  .001) and
uoroscopic times (49  20 min vs. 59  24 min, p  .001).
F recurrence after single procedure. After 21  7
onths of follow-up, 189 patients in group 1 (39%) and 319
n group 2 (32%) had arrhythmia recurrence (p  0.005).
hen stratified by AF type, patients with NPAF in group
had significantly higher failure compared with those in
roup 2 (150 [46%] and 257 [35%], p  0.002) (Fig. 1),
hereas no difference existed in the PAF subgroup (39 [25%]
n group 1 vs. 62 [22%] in group 2, p  0.295) (Fig. 2).
mong patients with recurrence, the distribution of arrhyth-
ia type was similar across both groups (AF 41%, AFL 38%,
T 15%, and AF or AFL 6% in patients with MS vs. AF 36%,
FL 43%, AT 13%, and AF or AFL 8% in those without MS,
 0.05). Kaplan-Meier survival curves showing each group’s
umulative probability of AF-free survival are presented in
igures 1 and 2.
oL. Compared with group 2, group 1 had significantly
ower baseline scores on all SF-36 Health Survey subscales
Table 2). At 1-year follow-up, both MCS (5.7  2.5,
 0.001), and PCS (9.1  3.7, p  0.001) scores showed
mprovement in patients in group 1, whereas only MCS scores
4.6  2.8, p  0.036) were improved in group 2.
mpact of ablation success on change in QoL at follow-up.
or patients with successful ablation, 1-year PCS and MCS
cores demonstrated substantial improvement in both
roups (MS and no MS). No statistically significant change
as noted among those in whom ablation failed (Table 3).
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MS and Ablation Outcome in AF April 3, 2012:1295–301Predictors of arrhythmia recurrence on multivariate
analysis. Multivariate analysis for recurrence-free survival was
performed using Cox proportional hazards modeling. The
covariates in the model are described in the section on
statistical analysis. After adjusting for important confounders,
presence of MS (HR: 1.28; 95% CI: 1.04 to 1.57; p 0.021),
ex (female) (HR: 1.39; 95% CI: 1.13 to 1.71; p 0.002), and
PAF (HR: 1.51; 95% CI: 1.24 to 1.59; p  0.001) demon-
trated significant association with arrhythmia recurrence.
Subanalysis assessing possible predictors of recurrence in
he PAF and NPAF populations revealed that MS (HR:
.42; 95% CI: 1.04 to 1.67; p  0.022), sex (HR: 1.28; 95%
I: 1.02 to 2.17; p  0.033), CRP 0.9 mg/dl (HR: 1.87;
5% CI: 1.34 to 3.71; p  0.002), and WBC count (HR:
.22; 95% CI: 1.01 to 1.86; p  0.016) were independent
redictors of AF or AT recurrence in patients with NPAF.
However, in patients with PAF, presence of MS (HR:
.08; 95% CI: 0.71 to 1.63; p  0.731), CRP 0.9 mg/dl
Baseline Population CharacteristicsTable 1 Baseline Population Characteristics
Variable
Group 1 (With
(n  485)
Age (yrs) 64 8
Male 373 (77%)
AF type
PAF 156 (32%)
PER AF 116 (24%)
LSP AF 213 (44%)
AF duration (months) 62 (30–78)
BMI (kg/m2)* 31 5
Dyslipidemia* 456 (94%)
Hypertension* 462 (95%)
Diabetes* 43 (9%)
CHF 68 (14%)
Prior stroke/TIA 29 (6%)
CAD 73 (15%)
OSA 68 (14%)
LA diameter (mm) 44.1 7.1
LVEF (%) 55 12
WBC (per mm3) 6,880 1,03
CRP (mg/dl) 5.18 (0.39–8.
Follow-up (months) 21 6
Pacemaker/ICD implantation 19 (4%)
ACE inhibitors 398 (82%)
Beta-blockers 378 (78%)
Aspirin 281 (58%)
Lipid-lowering therapy 441 (91%)
INR at baseline 2.4 0.5
Fluoroscopic time (min) 56 24
RF time (min) 76 33
Procedural time (min) 162 60
Values mean SD, n (%), or median (interquartile range). *As defined
not appropriate for comparison across MS groups.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; BMI
failure; CRP  C-reactive protein; ICD  implantable cardioverter-d
long-standing persistent; LVEF  left ventricular ejection fraction; MS
atrial fibrillation; PER  persistent; RF  radiofrequency; TIA  transHR: 1.11; 95% CI: 0.38 to 2.06; p  0.436), and WBC oHR: 1.03; 95% CI: 0.78 to 2.09; p  0.204) failed to
redict recurrence.
Further analyses were performed to compare the predic-
ive performance of the composite measure (MS) with its
ndividual components. Table 4 shows the adjusted HR and
aximum likelihood estimate for each of the covariates. In
ur series, the model with MS exhibited significant associ-
tion with arrhythmia recurrence, while the alternative
odel with individual components showed relatively smaller
egression coefficients and no significant association.
omplications. During ablation, 4 (0.82%) and 7
0.69%) pericardial effusions were reported in groups 1
nd 2, respectively (p  0.779). Additionally, 1 groin
ematoma in group 1 and 1 pseudoaneurysm each in
roups 1 and 2 were seen.
iscussion
n the present study, we aimed to examine the impact of MS
Group 2 (Without MS)
(n  1,011) p Value
62 10 0.076
728 (72%) 0.044
283 (28%) 0.115
277 (27%) 0.960
451 (45%) 0.141
58 (24–80) 0.424
27 6 —
394 (39%) —
320 (32%) —
27 (3%) —
51 (5%) 0.001
51 (5%) 0.451
111 (11%) 0.019
115 (11%) 0.144
42.8 7.6 0.003
57 9 0.128
6,572 1,007 0.034
3.24 (0.31–6.82) 0.017
21 8 0.910
45 (5%) 0.633
283 (28%) 0.001
374 (37%) 0.001
273 (27%) 0.001
303 (30%) 0.001
2.4 7 0.941
55 23 0.332
72 36 0.050
157 46 0.469
Methods” section, these variables are the components of MS and are
mass index; CAD  coronary artery disease; CHF  congestive heart
tor; INR  international normalized ratio; LA  left atrial; LSP 
abolic syndrome; OSA  obstructive sleep apnea; PAF  paroxysmal
hemic attack; WBC  white blood cell.MS)
0
43)
in the “
 body
efibrillan long-term ablation outcomes in patients with AF. As a
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April 3, 2012:1295–301 MS and Ablation Outcome in AFsecondary analysis, we included measurements of CRP and
total WBC count in the study and assessed their influence
on ablation outcomes as well. Inflammation being a close
associate of both MS and AF, this step was justified.
Our main observations were as follows. First, in the
overall population, MS was associated with significantly
higher AF recurrence. Second, when stratified by AF type,
in the NPAF cohort, patients with MS had a higher
recurrence rate compared with those without MS. This
Figure 1 Recurrence-Free Survival in Patients With NPAF
Kaplan-Meier curve showing the probability of survival free of atrial fibrillation or
atrial tachycardia after the first procedure across study groups in patients with
nonparoxysmal atrial fibrillation (NPAF). MS  metabolic syndrome.
Figure 2 Recurrence-Free Survival in Patients With PAF
Kaplan-Meier curve showing the probability of survival free of atrial fibrillation or
atrial tachycardia after the first procedure across study groups in patients with
paroxysmal atrial fibrillation (PAF). MS  metabolic syndrome.association was not observed in the PAF subgroup. Third,
multivariate analysis demonstrated AF type, presence of
MS, and female sex to be independently associated with
failure. Fourth, more impairment in baseline QoL and
larger improvements in follow-up assessments were ob-
served in patients presenting with MS. Last, in the NPAF
subgroup, baseline CRP, WBC count, and presence of MS
were independent predictors of AF recurrence. This was not
observed in patients with PAF.
The pathogenesis of AF is known to be an interplay of 2
factors: initiating triggers from ectopic foci and an abnormal
arrhythmogenic substrate that mostly arises from structural
remodeling of heart (10). As is well evident by now, 2 types
of atrial remodeling take place in AF, leading to mainte-
nance and perpetuation of the arrhythmia: electrical and
structural remodeling. Electrical remodeling includes short-
ening of the atrial refractory period, the loss of rate
adaptation, prolongation of atrial conductivity, and accumu-
lation of calcium within atrial myocytes, which result in the
promotion and continuance of multiple wavelet re-entry
circuits (11).
Structural remodeling runs in parallel with electrical
remodeling and includes left atrial dilation and increased
atrial fibrosis (11). Fibrosis leads to the separation of
myocytes from one another, which significantly impairs the
transmission of electrical signals at the cellular level and
results in chaotic atrial conduction (12).
Inflammation, fibrosis, and oxidative stress seem to play a
crucial interactive role in remodeling-induced abnormalities
that result in the perpetuation of arrhythmia, giving rise to
persistent AF or long-standing persistent AF (10,13). Be-
cause all components of MS are closely associated with
inflammation, MS logically seems to be related to atrial
remodeling. In fact, several earlier studies have demon-
strated left atrial diameters to be significantly larger in
patients with AF with MS than in those without it (14,15).
We also observed a similar trend in the present study.
Metabolic and hemodynamic variations associated with MS
are known to lead to enlargement of the left atrium (16).
Wang et al. (17) suggested that left atrial diameter consti-
tutes an intermediate phenotype that favors AF in the MS
population. An earlier study by Bhargava et al. (18) indi-
Baseline QoL Score by Study GroupTable 2 Baseline QoL Score by Study Group
QoL Domain Group 1 (With MS) Group 2 (Without MS) p Value
Physical functioning 74.5 28.4 79.3 31.1 0.019
Role physical 62.5 43.7 76.6 38.5 0.001
Role emotional 67.5 41.3 74.5 39.1 0.003
Vitality 51.4 31.6 59.7 29.6 0.001
Mental health 69.2 21.3 75.3 19.4 0.001
Social functioning 76.1 28.4 79.1 26.1 0.038
Bodily pain 79.4 22.6 74.3 29.1 0.002
General health 65.3 21.0 70.1 19.2 0.001
Values are mean  SD.
MS  metabolic syndrome; QoL  quality of life.cated that MS may have a more pertinent role in the
ummar
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MS and Ablation Outcome in AF April 3, 2012:1295–301pathogenesis of persistent or long-standing persistent AF,
possibly resulting in a higher recurrence rate after catheter
ablation in those AF subtypes than in PAF. The exact
mechanism by which MS influences the perpetuation of AF
resulting in higher arrhythmia recurrence, is still not very
clear. Possibly, it has some direct or indirect influence on
atrial electrophysiology. Kipshidze et al. (19) proposed that
the dispersion of refractoriness between the right and left
atria, caused by MS, directly triggers the development of
AF. Furthermore, Oliveira et al. (20) postulated that the
dispersion of refractoriness may be one of the mechanisms
that lead to the maintenance of AF, depending on the
degree of electrical homogeneity of the atrial tissue and the
number of re-entry wavelets.
Elevated risk for recurrence and a higher frequency of
non-PV triggers have been reported to be associated with
NPAF (18). We observed more non-PV triggers and higher
recurrence in the NPAF cohort of group 1 compared with
that of group 2. Obesity, a prominent component of MS,
has been demonstrated to be prevalently associated with
non-PV triggers (21). Because non-PV triggers are more
challenging to eliminate, this could have contributed to the
observed higher recurrence rate in the NPAF subgroup of
group 1.
In a multivariate analysis, we found MS, as a composite
measure, but not its individual components, to be associated
with AF recurrence. An earlier study demonstrated MS to
be an independent predictor, whereas no association was
reported between components of MS and AF recurrence,
except BMI 25 kg/m2 (22). In a separate study, Tang et
al. (23) reported BMI 25 kg/m2 to be a univariate but not
independent predictor AF recurrence, whereas MS as a
group was.
Our study demonstrated inflammatory markers such as
CRP and WBC count, along with MS, to be independent
Change in QoL at Follow-Up by Recurrence StatTable 3 Change in QoL at Follow-Up by Rec
Recurrence Status
Group 1
Change From Baseline
MCS, no recurrence 12.8 9.6
MCS, recurrence 03.1 11.6
PCS, no recurrence 08.2 3.5
PCS, recurrence 02.4 10.3
Values are mean  SD.
MCS  mental component summary; PCS  physical component s
Parameter Estimates and HRs FromMultivariate Cox R gression ModelsTable 4 Param ter Estimates and HRs FromMultivariate Cox Regression Models
Predictor Regression Coefficient HR p Value
MS 0.401 1.28 0.021
Hypertension 0.157 1.09 0.364
BMI 25 kg/m2 0.322 1.14 0.118
Dyslipidemia 0.231 1.13 0.141
Diabetes 0.090 1.08 0.246BMI  body mass index; HR  hazard ratio; MS  metabolic syndrome.predictors of failure in patients with NPAF only. In a
meta-analysis of 16 trials, Boos et al. (11) suggested an
intricate and close association of inflammation with persis-
tent and long-standing persistent AF (24). Previous studies
have also shown that CRP levels are related to left atrial size
and AF duration before cardioversion (25,26). Longer AF
duration results in more atrial structural remodeling (25),
which serves as an arrhythmogenic substrate leading to the
perpetuation of AF. Our findings corroborate these obser-
vations. Therefore, it is reasonable to state with prudence
that the mechanism linking MS to a higher recurrence rate
in NPAF is mediated via inflammation. Why inflammatory
markers failed to predict outcomes in patients with PAF is
not known. But it can be speculated that differential
expression of biomarkers due to a lower frequency of
associated comorbidities could have resulted in such failure.
Several independent studies have reported associations of
poor QoL with either MS or AF (6,27) separately. This is
the first study to examine the impact of MS on QoL in
patients with AF. Lower baseline scores and higher post-
ablation improvement of QoL were seen in the MS group in
our study. Inflammatory markers, enhanced hypothalamus-
pituitary-adrenal axis activity, as well as simply being labeled
with an additional disease (components of MS) are reported
to account for the association between MS and lower QoL
(6,28).
A lower baseline score has been reported to be associated
with more robust improvement in QoL (29,30). In this
study, we observed a similar trend; patients with MS had
lower baseline QoL scores, and they demonstrated signifi-
cant improvement on follow-up. With AF and components
of MS intruding daily life by imposing physical, mental, and
social limitations, the lower pre-intervention QoL scores
were well anticipated in group 1. After catheter ablation,
these patients perceived a greater improvement in QoL, as
they experienced huge changes in their capabilities to
overcome hardships in daily life because of the elimination
of AF symptoms and the frequent use of health care
resources. In group 2, patients experienced improvements in
only the mental score components of the SF-36 Health
Survey; physical components did not exhibit any noticeable
changes. It is known that diabetes and obesity affect the
physical domains of functioning most profoundly (6,30).
Therefore, it can be cautiously speculated that because a
ce Status
Group 2
Value Change From Baseline p Value
.0001 10.2 4.5 0.0001
.525 02.5 10.6 0.413
.014 06.2 3.8 0.034
.436 03.4 14.3 0.653
y; QoL  quality of life.usurren
p
0
0
0
0significantly lower proportion of patients in group 2 had
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
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ing was much higher and thus the post-ablation improve-
ment was not perceived as something as dramatic, as it was
in group 1.
Study limitations. This study was limited in several re-
spects. First, a single generic questionnaire was used to
assess QoL. Disease-specific instruments would have con-
tributed complementarily toward capturing subtle differ-
ences in different patient groups with 1 or more components
of MS. Second, patients were not followed for any status
changes in their MS components, and thus any influence of
changes on ablation outcomes cannot be ruled out. Last, we
did not obtain waist circumference measurement data,
which would have illustrated the abdominal obesity status of
the patients, which is considered by some as a better tool to
assess obesity.
Conclusions
This study demonstrated a strong association between AF
recurrence and components of MS, as well as conventional
inflammatory markers such as CRP and WBC count, in
patients with NPAF undergoing catheter ablation. No such
association was observed in patients with PAF. Addition-
ally, the presence of MS was associated with lower baseline
QoL, which improved substantially after ablative treatment
for AF.
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